Minimal residual disease in chronic myeloid leukemia

N Engl J Med. 2003 Oct 9;349(15):1399-401. doi: 10.1056/NEJMp038130.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzamides
  • Biomarkers, Tumor / blood
  • Cytarabine / therapeutic use
  • Fusion Proteins, bcr-abl / blood*
  • Genes, abl
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transcription, Genetic

Substances

  • Antineoplastic Agents
  • Benzamides
  • Biomarkers, Tumor
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Cytarabine
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl